1. 'Stapling' scFv for multispecific biotherapeutics of superior properties
- Author
-
Lauren E. Boucher, Elisabeth Geyer Prinslow, Michael Feldkamp, Fang Yi, Rupesh Nanjunda, Sheng-Jiun Wu, Tun Liu, Eilyn R. Lacy, Steven Jacobs, Natalia Kozlyuk, Brian Del Rosario, Bingyuan Wu, Patricia Aquino, Robert C. Davidson, Samantha Heyne, Nicholas Mazzanti, James Testa, Michael D. Diem, Elsa Gorre, Andrew Mahan, Hirsh Nanda, Harsha P. Gunawardena, Alexis Gervais, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang, Adam Zwolak, Partha Chowdhury, Wan Cheung Cheung, and Jinquan Luo
- Subjects
Multi-specific antibody ,Scfv ,Scfv stabilization ,Single chain fv ,Spfv ,Stapled scfv ,Therapeutics. Pharmacology ,RM1-950 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ABSTRACTSingle-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains exhibit lower stability and increased risk of aggregation due to transient dissociation (“breathing”) and inter-molecular reassociation of the two domains (VL and VH). We designed a novel strategy, referred to as stapling, that introduces two disulfide bonds between the scFv linker and the two variable domains to minimize scFv breathing. We named the resulting molecules stapled scFv (spFv). Stapling increased thermal stability (Tm) by an average of 10°C. In multiple scFv/spFv multispecifics, the spFv molecules display significantly improved stability, minimal aggregation and superior product quality. These spFv multispecifics retain binding affinity and functionality. Our stapling design was compatible with all antibody variable regions we evaluated and may be widely applicable to stabilize scFv molecules for designing biotherapeutics with superior biophysical properties.
- Published
- 2023
- Full Text
- View/download PDF